The UK and US have reached a major trade agreement that will guarantee no import taxes on UK medicine exports being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to raise spending on medicines through the public health system. This commitment guarantees that duties on these vital goods will stay at nothing for a duration of 36 months.
This development is in response to recent statements to hike import taxes on branded pharmaceutical products, with potential rates floated up to 100%.
"This deal with the United Kingdom strengthens the worldwide climate for new treatments and brings much-needed balance to American-British pharmaceutical trade," a statement said.
Trade Significance
Medicines represent one of the UK's largest goods shipped to the United States, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Export figures show that in the year to the end of the third quarter, the UK exported medicines valued at billions to the US. This figure accounted for 17.4% of British export trade in that span.
"This agreement secures work, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The agreement includes several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to increase overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates were more than 20%.
Broader Context
The deal follows a long-running tension between the sector and the ministers over medicine costs and regulatory access.
These tensions were intensified by assertions that American customers were charged significantly more for the identical medicines than people in the other developed nations.
Recently, several major drug company projects in the UK have been halted or cancelled, while substantial expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
